Yuflyma (Adalimumab-Aaty) for Psoriasis and Psoriatic Arthritis

Yuflyma (adalimumab-aaty) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis or active psoriatic arthritis.

How Yuflyma Works and How It’s Taken

Yuflyma is a type of medication called a tumor necrosis factor (TNF) blocker. It works by binding to TNF-alpha, a protein involved in inflammation. By blocking TNF-alpha, Yuflyma helps reduce inflammation.

In people with plaque psoriasis, treatment may reduce skin thickening and the buildup of inflammatory cells in the skin.

Doctors prescribe Yuflyma when adults have moderate to severe chronic plaque psoriasis, need treatment that works throughout the body or light therapy, and other treatments are less appropriate. They also prescribe it for adults with active psoriatic arthritis.

Yuflyma is a biosimilar of Humira. This means it is made from living cells and is designed to work like the original medicine. The FDA requires biosimilars to have no meaningful differences in safety or how well they work.

Yuflyma is given as an injection under the skin, usually every other week. With proper training and a doctor’s guidance, people or caregivers may give the injections at home.

Typical Dosing for Psoriasis

The recommended starting dose of Yuflyma for psoriasis is 80 milligrams. One week later, treatment continues with 40 milligrams every other week.

This information is based on prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.

Yuflyma Side Effects

The most common side effects of Yuflyma occurred in more than 10 percent of people. These side effects were:

Infections, such as upper respiratory infections and sinus infections
Injection site reactions, such as redness or discoloration, itching, bleeding, pain, or swelling where the shot is given
Headache
Rash

Serious Side Effects and Warnings

Yuflyma can cause serious side effects that may require immediate medical attention. These include:

Serious infections — Because Yuflyma affects the immune system, infections can become severe, including tuberculosis and invasive fungal infections.
Malignancies — Some people may develop lymphoma or other cancers.
Hypersensitivity reactions — Severe allergic reactions such as anaphylaxis or angioedema can occur and may cause swelling and trouble breathing.
Hepatitis B virus reactivation — The virus can become active again in people who carry it.
Demyelinating disorders — These rare nervous system problems affect the protective covering of nerves and may include optic neuritis or Guillain-Barré syndrome.
Blood problems — Rare but serious low blood cell counts can occur, which may lead to easy bruising, bleeding, or persistent fever.
New or worsening heart failure — The heart may not pump as well, leading to symptoms such as shortness of breath or swelling.
Autoimmune reactions — Some people may develop a lupuslike syndrome or autoimmune hepatitis, in which the immune system attacks the body.

Get medical help right away if you think you are having a serious reaction.

How To Save on Yuflyma

Celltrion USA offers the Celltrion CARES Co-Pay Assistance Program. Eligible people with commercial insurance may pay as little as $0 for each one-month prescription.

The Celltrion CARES Co-Pay Assistance Program provides copay savings for Yuflyma, while the Celltrion CONNECT Patient Support Program offers personalized help with insurance, prior authorization and appeal support, financial support, and day-to-day resources. To learn more, visit the Celltrion CARES Co-Pay Assistance Program or the Celltrion CONNECT Patient Support Program, or call 877-812-6662.

What To Know Before Taking Yuflyma

Before starting Yuflyma, your doctor will check you for active tuberculosis (TB) and test for latent (hidden) TB. If you are at risk for hepatitis B virus (HBV) infection, your doctor may evaluate you for prior HBV infection before treatment.

If possible, people should be up to date on recommended vaccines before starting Yuflyma. Do not receive live vaccines while using Yuflyma.

Tell your doctor if you have any allergies to adalimumab or any ingredients in Yuflyma.

Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.

Tell your doctor if you:

Have an infection or get infections that keep coming back
Have been exposed to TB or have risk factors for TB
Have had hepatitis B
Have a history of certain nerve problems, such as multiple sclerosis
Live in or have traveled to areas where fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis, are common
Have heart failure
Have a history of cancer
Use abatacept (Orencia), anakinra (Kineret), rituximab (Rituxan), azathioprine (Imuran), or mercaptopurine (Purinethol, 6-MP)
Are scheduled to have major surgery

Do not start Yuflyma if you have an active infection.

Yuflyma is also FDA-approved to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, hidradenitis suppurativa, noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

If you miss a dose, take it as soon as you can. Then return to your regular dosing schedule.

If you are pregnant, planning to become pregnant, or breastfeeding while taking Yuflyma, talk with your doctor about the risks and benefits.

Community FAQs

These answers are fact-checked by our editorial staff.

How effective is Yuflyma for psoriasis?

In a study of adults with plaque psoriasis, 71 percent of people treated with adalimumab reached PASI 75 at week 16, compared with 7 percent of people who took placebo (an inactive treatment). PASI 75 means at least a 75 percent improvement in psoriasis severity. Also at week 16, 62 percent of people treated with adalimumab were rated clear or minimal, compared with 4 percent of people taking placebo.

How effective is Yuflyma for psoriatic arthritis?

In a clinical study of adults with psoriatic arthritis, 57 percent of people treated with adalimumab achieved an ACR20 response (at least a 20 percent improvement in arthritis symptoms) at week 24, compared with 15 percent of people who received placebo. At week 24, 39 percent of people treated with adalimumab achieved an ACR50 response and 23 percent achieved an ACR70 response, compared with 6 percent and 1 percent of people who received placebo.

Among participants whose psoriasis affected at least 3 percent of their body surface area, 59 percent achieved PASI 75 and 42 percent achieved PASI 90 at week 24, compared with 1 percent and 0 percent of people who received placebo. PASI 75 and PASI 90 indicate at least 75 percent and 90 percent improvement in psoriasis severity.

Should I take Yuflyma for psoriasis or psoriatic arthritis if I have an infection?

Do not start Yuflyma if you have an active infection, including a localized infection. This medicine can lower your immune system’s ability to fight infections and can raise the risk of serious infections, including tuberculosis, fungal infections, and other bacterial or viral infections. Contact your doctor if you develop signs or symptoms of infection during treatment.